- Home
- MRNA vs TDG Comparison
MRNA vs TDG Comparison
Compare MRNA & TDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | TDG |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 69.5B |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MRNA | TDG |
|---|---|---|
| Price | $154.25 | $1,085.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 14 |
| Target Price | $34.27 | ★ $1,559.69 |
| AVG Volume (30 Days) | ★ 23.7M | 346.4K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 7.88% |
| EPS Growth | 21.77 | ★ 25.21 |
| EPS | N/A | ★ 25.20 |
| Revenue | ★ $19,263,000,000.00 | $8,831,000,000.00 |
| Revenue This Year | $9.36 | $15.19 |
| Revenue Next Year | $15.43 | $8.64 |
| P/E Ratio | ★ N/A | $42.70 |
| Revenue Growth | 4.29 | ★ 11.22 |
| 52 Week Low | $22.28 | $1,071.25 |
| 52 Week High | $176.66 | $1,463.03 |
Technical Indicators
Market Signals| Indicator | MRNA | TDG |
|---|---|---|
| Relative Strength Index (RSI) | 64.57 | 28.51 |
| Support Level | $46.85 | N/A |
| Resistance Level | $156.42 | $1,353.06 |
| Average True Range (ATR) | 9.54 | 23.55 |
| MACD | -1.67 | -5.67 |
| Stochastic Oscillator | 78.72 | 11.01 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About TDG Transdigm Group Incorporated
TransDigm manufactures and services a broad set of specialized parts for commercial and military aircraft. The firm has three segments: power and control, airframes, and a small nonaviation segment, which serves mostly off-road vehicles and mining equipment. It is an acquisitive holding company focused on buying up smaller firms that make proprietary aerospace products with substantial aftermarket revenue. TransDigm regularly employs financial leverage to amplify its operating results.